Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091878 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4ELTA4HCYP3A4MAPK14 | |
| SCHEMBL23410797 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4ELTA4HCYP3A4MAPK14 | |
| SCHEMBL5095734 | 0.93 | L3MBTL1 (0.47) | SMN1; SMN2KDM4ELTA4HCTBP2L3MBTL1 | |
| SCHEMBL4459265 | 0.93 | L3MBTL1 (0.47) | SMN1; SMN2KDM4ELTA4HCTBP2L3MBTL1 | |
| SCHEMBL4459267 | 0.93 | L3MBTL1 (0.47) | SMN1; SMN2KDM4ELTA4HCTBP2L3MBTL1 | |
| SCHEMBL7423263 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM4ECTBP2L3MBTL1XDH | |
| SCHEMBL8865628 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM4ECTBP2L3MBTL1XDH | |
| SCHEMBL9324776 | 0.82 | KDM4E (0.46) | SMN1; SMN2KDM4ECYP3A4CTBP2XDH | |
| SCHEMBL9324768 | 0.82 | KDM4E (0.46) | SMN1; SMN2KDM4ECYP3A4CTBP2XDH | |
| SCHEMBL4586342 | 0.82 | ALDH1A1 (0.51) | SMN1; SMN2KDM4ECTBP2L3MBTL1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| EP-4065107-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| US-20060128759-A1 | Substituted isoxazole derivatives and their use in pharmaceutics | MERCKLE GMBH (DE) | 2006-06-15 | — | — | US | disclosed |
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2004-06-03 | — | — | US | disclosed |
| EP-0727998-B1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1306377-A2 | Pyridyl-oxazoles and their use as cytokines inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-6288062-B1 | INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-11 | — | — | US | disclosed |
| EP-0727998-A4 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0727998-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013067-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | IL2, IL17A, IL5 | SMN1; SMN2 2408/4885KDM4E 4530/4885LTA4H 136/4885 |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | IL17A, IL4I1, IL2 | SMN1; SMN2 283/4885KDM4E 4607/4885LTA4H 119/4885 |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | SMN1; SMN2 1/4885KDM4E 1310/4885LTA4H 3217/4885 |
| US-20060128759-A1 | Substituted isoxazole derivatives and their use in pharmaceutics | IFNG, IRF3, IL2 | SMN1; SMN2 4155/4885KDM4E 4044/4885LTA4H 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.